These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 34721403)

  • 21. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
    Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.
    Netti GS; Infante B; Spadaccino F; Godeas G; Corallo MG; Prisciandaro C; Croce L; Rotondi M; Gesualdo L; Stallone G; Grandaliano G; Ranieri E
    J Immunol Res; 2019; 2019():8483650. PubMed ID: 31781684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
    Mahmud M; Pinnschmidt HO; Reinhard L; Harendza S; Wiech T; Stahl RAK; Hoxha E
    PLoS One; 2019; 14(9):e0221293. PubMed ID: 31498806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
    Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
    Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
    [No Abstract]   [Full Text] [Related]  

  • 26. Association Between High NK-Cell Count and Remission of Primary Membranous Nephropathy: A Retrospective Chart Review and Pilot Study.
    Chen W; Cai J; Raffetseder U; Zhu B; Chen J; Song N; Li Y; Lu Y; Fang Y; Ding X; Wang J
    Clin Ther; 2023 Apr; 45(4):364-374. PubMed ID: 36997447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membranous nephropathy: integrating basic science into improved clinical management.
    Cattran DC; Brenchley PE
    Kidney Int; 2017 Mar; 91(3):566-574. PubMed ID: 28065518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
    Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
    PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
    Ramachandran R; Kumar V; Kumar A; Yadav AK; Nada R; Kumar H; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
    Nephrol Dial Transplant; 2016 Sep; 31(9):1486-93. PubMed ID: 26673907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
    Seitz-Polski B; Payré C; Ambrosetti D; Albano L; Cassuto-Viguier E; Berguignat M; Jeribi A; Thouret MC; Bernard G; Benzaken S; Lambeau G; Esnault VL
    Nephrol Dial Transplant; 2014 Dec; 29(12):2334-42. PubMed ID: 25063424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membranous Nephropathy: Updates on Management.
    Bharati J; Waguespack DR; Beck LH
    Adv Kidney Dis Health; 2024 Jul; 31(4):299-308. PubMed ID: 39084755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P
    Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.